Stock Track | BioLife Solutions Soars 5.10% After Strong Q4 Earnings and Positive 2025 Outlook

Stock Track

2025/03/05

BioLife Solutions (BLFS) stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.

The life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:

37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million
31% year-over-year increase in total Q4 2024 revenue to $22.7 million
Improved GAAP gross margin of 60% in Q4 2024, up from 53% in Q4 2023
Positive adjusted EBITDA of $4 million in Q4 2024, up from $3.7 million in Q4 2023
Narrowed GAAP net loss in Q4 2024 to $2 million or $0.04 per share, compared to $7.2 million or $0.16 per share in Q4 2023

The company's strong performance was driven by the successful divestiture of non-core product lines, resulting in a leaner and more focused business. BioLife Solutions also provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, representing 16% to 20% growth over 2024. This growth is expected to be fueled by the company's cell processing platform, with anticipated revenue of $86.5 million to $89 million, an 18% to 21% increase from the previous year.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1186348054"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1186348054\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1186348054?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 02:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186348054","market":"hk","top_or_hot":-1,"title":"Stock Track | BioLife Solutions Soars 5.10% After Strong Q4 Earnings and Positive 2025 Outlook","media":"Stock Track","content":"<p>BioLife Solutions (BLFS) stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.</p>\n\n<p>The life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:\n<ul>\n<li>37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million</li>\n<li>31% year-over-year increase in total Q4 2024 revenue to $22.7 million</li>\n<li>Improved GAAP gross margin of 60% in Q4 2024, up from 53% in Q4 2023</li>\n<li>Positive adjusted EBITDA of $4 million in Q4 2024, up from $3.7 million in Q4 2023</li>\n<li>Narrowed GAAP net loss in Q4 2024 to $2 million or $0.04 per share, compared to $7.2 million or $0.16 per share in Q4 2023</li>\n</ul>\n</p>\n\n<p>The company's strong performance was driven by the successful divestiture of non-core product lines, resulting in a leaner and more focused business. BioLife Solutions also provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, representing 16% to 20% growth over 2024. This growth is expected to be fueled by the company's cell processing platform, with anticipated revenue of $86.5 million to $89 million, an 18% to 21% increase from the previous year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioLife Solutions Soars 5.10% After Strong Q4 Earnings and Positive 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioLife Solutions Soars 5.10% After Strong Q4 Earnings and Positive 2025 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-05 02:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioLife Solutions (BLFS) stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.</p>\n\n<p>The life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:\n<ul>\n<li>37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million</li>\n<li>31% year-over-year increase in total Q4 2024 revenue to $22.7 million</li>\n<li>Improved GAAP gross margin of 60% in Q4 2024, up from 53% in Q4 2023</li>\n<li>Positive adjusted EBITDA of $4 million in Q4 2024, up from $3.7 million in Q4 2023</li>\n<li>Narrowed GAAP net loss in Q4 2024 to $2 million or $0.04 per share, compared to $7.2 million or $0.16 per share in Q4 2023</li>\n</ul>\n</p>\n\n<p>The company's strong performance was driven by the successful divestiture of non-core product lines, resulting in a leaner and more focused business. BioLife Solutions also provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, representing 16% to 20% growth over 2024. This growth is expected to be fueled by the company's cell processing platform, with anticipated revenue of $86.5 million to $89 million, an 18% to 21% increase from the previous year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLFS","symbol_name":"BioLife Solutions Inc.","start_time":0,"source_url":"","article_id":"1186348054","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186348054","pubTimestamp":1741111832,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BioLife Solutions  stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.The life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:. 37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million. 31% year-over-year increase in total Q4 2024 revenue to $22.7 million. Improved GAAP","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLFS":"BioLife Solutions Inc."},"translate_title":"股票赛道BioLife Solutions在强劲的第四季度盈利和积极的2025年前景后飙升5.10%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLFS":1},"content_text":"BioLife Solutions (BLFS) stock surged 5.10% in intraday trading on Tuesday, following the release of its Q4 2024 earnings report and positive financial guidance for 2025.\nThe life sciences company posted impressive results for the fourth quarter and full year 2024, with significant improvements in key financial metrics. Highlights included:\n\n37% year-over-year growth in Q4 2024 cell processing revenue to $20.3 million\n31% year-over-year increase in total Q4 2024 revenue to $22.7 million\nImproved GAAP gross margin of 60% in Q4 2024, up from 53% in Q4 2023\nPositive adjusted EBITDA of $4 million in Q4 2024, up from $3.7 million in Q4 2023\nNarrowed GAAP net loss in Q4 2024 to $2 million or $0.04 per share, compared to $7.2 million or $0.16 per share in Q4 2023\n\nThe company's strong performance was driven by the successful divestiture of non-core product lines, resulting in a leaner and more focused business. BioLife Solutions also provided optimistic guidance for 2025, projecting revenue between $95.5 million and $99 million, representing 16% to 20% growth over 2024. This growth is expected to be fueled by the company's cell processing platform, with anticipated revenue of $86.5 million to $89 million, an 18% to 21% increase from the previous year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}